Preoperative intravitreal bevacizumab effects on the course of Pars Plana vitrectomy in diabetic vitreous hemorrhage
Purpose To compare the rate of rehemorrhage in patients with diabetic vitreous hemorrhage (VH) undergoing pars plana vitrectomy (PPV) with versus without preoperative intravitreal bevacizumab (IVB) injection Methods Forty patients with proliferative diabetic retinopathy (40 eyes) with an indication...
Gespeichert in:
| Veröffentlicht in: | Acta ophthalmologica (Oxford, England) England), 2015-10, Vol.93 (S255), p.n/a |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | S255 |
| container_start_page | |
| container_title | Acta ophthalmologica (Oxford, England) |
| container_volume | 93 |
| creator | Zahaf, A. Zghal, I. Fekih, O. Zayani, M. Mahjoub, A. Bouguila, H. Nacef, L. |
| description | Purpose
To compare the rate of rehemorrhage in patients with diabetic vitreous hemorrhage (VH) undergoing pars plana vitrectomy (PPV) with versus without preoperative intravitreal bevacizumab (IVB) injection
Methods
Forty patients with proliferative diabetic retinopathy (40 eyes) with an indication for primary vitrectomy were randomized to IVB group (20 eyes) or control group (20 eyes). Intravitreal bevacizumab group received intravitreal injection of 1.25 mg/0.05 mL bevacizumab, 1 week before vitrectomy
Results
The frequency of postoperative recurrent vitreous hemorrhage (5%, 1/20 vs. 40%, 8/20, P = 0.017) were significantly lower in IVB group than in control group .The number of intraoperative endodiathermy spots (0.63 ± 1.0 vs. 1.3 ± 1.4, P = 0.028) were also significantly lower in IVB group than in control group while mean bleeding frequency in IVB group was 0.7 ± 0.78 times/case with range between 0 and 2 bleeding attacks/case and mean bleeding frequency in control group was 3.12 ± 1.31 times/case with range between 3 and 6 bleeding attacks/case and the difference was statistically significant as (p |
| doi_str_mv | 10.1111/j.1755-3768.2015.0695 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1715755094</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3815687131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1725-7b94f12b9bb555bcd9b78a66350af0b0a9b02435e2eb4c2734f09a90e8d2fcd43</originalsourceid><addsrcrecordid>eNqNkN9LwzAQgIsoOKd_ghDwuTNpm3bxbQx_wWADFXwLSXpxKW0zk3Qy_3rbVXz2Xu447rs7vii6JnhG-ritZqSgNE6LfD5LMKEznDN6Ek3-uqd_NX0_jy68rzDOSZ5nkyhsHNgdOBHMHpBpgxN7ExyIGknYC2W-u0ZIBFqDCh7ZFoUtIGU75wFZjTbCebSpRSvQkVPBNod-DyqNkBCMGtu282gLjXVuKz7gMjrTovZw9Zun0dvD_evyKV6tH5-Xi1WsSJHQuJAs0ySRTEpKqVQlk8Vc5HlKsdBYYsEkTrKUQgIyU0mRZhozwTDMy0SrMkun0c24d-fsZwc-8Kp_vO1PclIQ2ivBbJii45Ry1nsHmu-caYQ7cIL5IJhXfNDHB5V8EMwHwT13N3JfpobD_yC-WL8c4R-le4JK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1715755094</pqid></control><display><type>article</type><title>Preoperative intravitreal bevacizumab effects on the course of Pars Plana vitrectomy in diabetic vitreous hemorrhage</title><source>Wiley Free Content</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zahaf, A. ; Zghal, I. ; Fekih, O. ; Zayani, M. ; Mahjoub, A. ; Bouguila, H. ; Nacef, L.</creator><creatorcontrib>Zahaf, A. ; Zghal, I. ; Fekih, O. ; Zayani, M. ; Mahjoub, A. ; Bouguila, H. ; Nacef, L.</creatorcontrib><description>Purpose
To compare the rate of rehemorrhage in patients with diabetic vitreous hemorrhage (VH) undergoing pars plana vitrectomy (PPV) with versus without preoperative intravitreal bevacizumab (IVB) injection
Methods
Forty patients with proliferative diabetic retinopathy (40 eyes) with an indication for primary vitrectomy were randomized to IVB group (20 eyes) or control group (20 eyes). Intravitreal bevacizumab group received intravitreal injection of 1.25 mg/0.05 mL bevacizumab, 1 week before vitrectomy
Results
The frequency of postoperative recurrent vitreous hemorrhage (5%, 1/20 vs. 40%, 8/20, P = 0.017) were significantly lower in IVB group than in control group .The number of intraoperative endodiathermy spots (0.63 ± 1.0 vs. 1.3 ± 1.4, P = 0.028) were also significantly lower in IVB group than in control group while mean bleeding frequency in IVB group was 0.7 ± 0.78 times/case with range between 0 and 2 bleeding attacks/case and mean bleeding frequency in control group was 3.12 ± 1.31 times/case with range between 3 and 6 bleeding attacks/case and the difference was statistically significant as (p < 0.001). The frequency of reoperation due to recurrent vitreous hemorrhage within 4 weeks after surgery was significantly lower (P = 0.022) in IVB group (5%, 1 patient) than in control group (35%, 7/20)
Conclusions
Intravitreal injection of 1.25 mg/0.05 mL bevacizumab 1 week before vitrectomy blocked vascular endothelial growth factor production in vitreous and significantly reduced the incidence of reoperation due to early postoperative recurrent vitreous hemorrhage.</description><identifier>ISSN: 1755-375X</identifier><identifier>EISSN: 1755-3768</identifier><identifier>DOI: 10.1111/j.1755-3768.2015.0695</identifier><language>eng</language><publisher>Malden: Wiley Subscription Services, Inc</publisher><subject>Ophthalmology</subject><ispartof>Acta ophthalmologica (Oxford, England), 2015-10, Vol.93 (S255), p.n/a</ispartof><rights>2015 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd</rights><rights>Copyright © 2015 Acta Ophthalmologica Scandinavica Foundation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1755-3768.2015.0695$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45551,46808</link.rule.ids></links><search><creatorcontrib>Zahaf, A.</creatorcontrib><creatorcontrib>Zghal, I.</creatorcontrib><creatorcontrib>Fekih, O.</creatorcontrib><creatorcontrib>Zayani, M.</creatorcontrib><creatorcontrib>Mahjoub, A.</creatorcontrib><creatorcontrib>Bouguila, H.</creatorcontrib><creatorcontrib>Nacef, L.</creatorcontrib><title>Preoperative intravitreal bevacizumab effects on the course of Pars Plana vitrectomy in diabetic vitreous hemorrhage</title><title>Acta ophthalmologica (Oxford, England)</title><description>Purpose
To compare the rate of rehemorrhage in patients with diabetic vitreous hemorrhage (VH) undergoing pars plana vitrectomy (PPV) with versus without preoperative intravitreal bevacizumab (IVB) injection
Methods
Forty patients with proliferative diabetic retinopathy (40 eyes) with an indication for primary vitrectomy were randomized to IVB group (20 eyes) or control group (20 eyes). Intravitreal bevacizumab group received intravitreal injection of 1.25 mg/0.05 mL bevacizumab, 1 week before vitrectomy
Results
The frequency of postoperative recurrent vitreous hemorrhage (5%, 1/20 vs. 40%, 8/20, P = 0.017) were significantly lower in IVB group than in control group .The number of intraoperative endodiathermy spots (0.63 ± 1.0 vs. 1.3 ± 1.4, P = 0.028) were also significantly lower in IVB group than in control group while mean bleeding frequency in IVB group was 0.7 ± 0.78 times/case with range between 0 and 2 bleeding attacks/case and mean bleeding frequency in control group was 3.12 ± 1.31 times/case with range between 3 and 6 bleeding attacks/case and the difference was statistically significant as (p < 0.001). The frequency of reoperation due to recurrent vitreous hemorrhage within 4 weeks after surgery was significantly lower (P = 0.022) in IVB group (5%, 1 patient) than in control group (35%, 7/20)
Conclusions
Intravitreal injection of 1.25 mg/0.05 mL bevacizumab 1 week before vitrectomy blocked vascular endothelial growth factor production in vitreous and significantly reduced the incidence of reoperation due to early postoperative recurrent vitreous hemorrhage.</description><subject>Ophthalmology</subject><issn>1755-375X</issn><issn>1755-3768</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqNkN9LwzAQgIsoOKd_ghDwuTNpm3bxbQx_wWADFXwLSXpxKW0zk3Qy_3rbVXz2Xu447rs7vii6JnhG-ritZqSgNE6LfD5LMKEznDN6Ek3-uqd_NX0_jy68rzDOSZ5nkyhsHNgdOBHMHpBpgxN7ExyIGknYC2W-u0ZIBFqDCh7ZFoUtIGU75wFZjTbCebSpRSvQkVPBNod-DyqNkBCMGtu282gLjXVuKz7gMjrTovZw9Zun0dvD_evyKV6tH5-Xi1WsSJHQuJAs0ySRTEpKqVQlk8Vc5HlKsdBYYsEkTrKUQgIyU0mRZhozwTDMy0SrMkun0c24d-fsZwc-8Kp_vO1PclIQ2ivBbJii45Ry1nsHmu-caYQ7cIL5IJhXfNDHB5V8EMwHwT13N3JfpobD_yC-WL8c4R-le4JK</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Zahaf, A.</creator><creator>Zghal, I.</creator><creator>Fekih, O.</creator><creator>Zayani, M.</creator><creator>Mahjoub, A.</creator><creator>Bouguila, H.</creator><creator>Nacef, L.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>201510</creationdate><title>Preoperative intravitreal bevacizumab effects on the course of Pars Plana vitrectomy in diabetic vitreous hemorrhage</title><author>Zahaf, A. ; Zghal, I. ; Fekih, O. ; Zayani, M. ; Mahjoub, A. ; Bouguila, H. ; Nacef, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1725-7b94f12b9bb555bcd9b78a66350af0b0a9b02435e2eb4c2734f09a90e8d2fcd43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Ophthalmology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zahaf, A.</creatorcontrib><creatorcontrib>Zghal, I.</creatorcontrib><creatorcontrib>Fekih, O.</creatorcontrib><creatorcontrib>Zayani, M.</creatorcontrib><creatorcontrib>Mahjoub, A.</creatorcontrib><creatorcontrib>Bouguila, H.</creatorcontrib><creatorcontrib>Nacef, L.</creatorcontrib><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Acta ophthalmologica (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zahaf, A.</au><au>Zghal, I.</au><au>Fekih, O.</au><au>Zayani, M.</au><au>Mahjoub, A.</au><au>Bouguila, H.</au><au>Nacef, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preoperative intravitreal bevacizumab effects on the course of Pars Plana vitrectomy in diabetic vitreous hemorrhage</atitle><jtitle>Acta ophthalmologica (Oxford, England)</jtitle><date>2015-10</date><risdate>2015</risdate><volume>93</volume><issue>S255</issue><epage>n/a</epage><issn>1755-375X</issn><eissn>1755-3768</eissn><abstract>Purpose
To compare the rate of rehemorrhage in patients with diabetic vitreous hemorrhage (VH) undergoing pars plana vitrectomy (PPV) with versus without preoperative intravitreal bevacizumab (IVB) injection
Methods
Forty patients with proliferative diabetic retinopathy (40 eyes) with an indication for primary vitrectomy were randomized to IVB group (20 eyes) or control group (20 eyes). Intravitreal bevacizumab group received intravitreal injection of 1.25 mg/0.05 mL bevacizumab, 1 week before vitrectomy
Results
The frequency of postoperative recurrent vitreous hemorrhage (5%, 1/20 vs. 40%, 8/20, P = 0.017) were significantly lower in IVB group than in control group .The number of intraoperative endodiathermy spots (0.63 ± 1.0 vs. 1.3 ± 1.4, P = 0.028) were also significantly lower in IVB group than in control group while mean bleeding frequency in IVB group was 0.7 ± 0.78 times/case with range between 0 and 2 bleeding attacks/case and mean bleeding frequency in control group was 3.12 ± 1.31 times/case with range between 3 and 6 bleeding attacks/case and the difference was statistically significant as (p < 0.001). The frequency of reoperation due to recurrent vitreous hemorrhage within 4 weeks after surgery was significantly lower (P = 0.022) in IVB group (5%, 1 patient) than in control group (35%, 7/20)
Conclusions
Intravitreal injection of 1.25 mg/0.05 mL bevacizumab 1 week before vitrectomy blocked vascular endothelial growth factor production in vitreous and significantly reduced the incidence of reoperation due to early postoperative recurrent vitreous hemorrhage.</abstract><cop>Malden</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/j.1755-3768.2015.0695</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1755-375X |
| ispartof | Acta ophthalmologica (Oxford, England), 2015-10, Vol.93 (S255), p.n/a |
| issn | 1755-375X 1755-3768 |
| language | eng |
| recordid | cdi_proquest_journals_1715755094 |
| source | Wiley Free Content; Wiley Online Library Journals Frontfile Complete |
| subjects | Ophthalmology |
| title | Preoperative intravitreal bevacizumab effects on the course of Pars Plana vitrectomy in diabetic vitreous hemorrhage |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T15%3A18%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preoperative%20intravitreal%20bevacizumab%20effects%20on%20the%20course%20of%20Pars%20Plana%20vitrectomy%20in%20diabetic%20vitreous%20hemorrhage&rft.jtitle=Acta%20ophthalmologica%20(Oxford,%20England)&rft.au=Zahaf,%20A.&rft.date=2015-10&rft.volume=93&rft.issue=S255&rft.epage=n/a&rft.issn=1755-375X&rft.eissn=1755-3768&rft_id=info:doi/10.1111/j.1755-3768.2015.0695&rft_dat=%3Cproquest_cross%3E3815687131%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1715755094&rft_id=info:pmid/&rfr_iscdi=true |